Product Discontinuation Notice

Dear Customer,

after careful consideration, QIAGEN has decided to discontinue the production of the aLF Reader with May 30, 2021 as final date of order placement and June 30, 2021 as final date of delivery. We will continue to provide lifecycle and service support until June 30, 2026.

While we regret any inconvenience this announcement may cause, we are pleased to supply you with alternate reader solutions for rapid testing from our subsidiary company DIALUNOX GmbH. Feel free to contact us for further questions.

Dentognostics Enters into Dental Partnership with QIAGEN

Dentognostics GmbH announced today that it has entered a partnership with QIAGEN Lake Constance today that will enable users of the new QIAGEN aLF Reader diagnostic device to recognize subclinical inflammation processes in their earliest stages by the quantitative assessment of the collagen-destroying enzyme aMMP8 directly on the patient. Measurement by QIAGEN’s reader is made from the ImplantSafeDR® Immuno-Assay, part of Dentognostics’ innovative aMMP8 lab-on-a-chip technology. The method is completely painless, takes only 30 seconds, and is completely sterile. It was developed in partnership with Professor Timo Sorsa and his research group at the University of Helsinki. It is performed on patients to protect their dental implants from damaging inflammation.

“Dentognostics is excited to be bringing our ImplantSafeDR test, an aMMP8-based assay, to market exclusively with QIAGEN’s aLF Reader,” said Dirk-Rolf Gieselmann, Chairman of the Dentognostic Group. “QIAGEN’s technical and market expertise make it an ideal partner for Dentognostics. We look forward to expanding the product’s reach through our partnership.”

“QIAGEN is delighted to team with Dentognostics to bring its dental ImplantSafeDR immunoassay and our aLF lateral flow reader to dentists and their patients across the EU,” said Michael Doumanas, Head of Sales and Marketing, QIAGEN Point-of-Need Systems. “Together, the ImplantSafeDR test and aLF reader enable dentists to detect periimplantitis in its earliest stages to better protect dental implants. We look forward to continuing to work with Dentognostics to bring this important, new method to market, which will directly benefit dentists and their patients.”

The new method developed through the QIAGEN partnership with Dentognostics supplements clinical diagnosis such as the periodontal screening index (PSI)/bleeding on probing (BOP) by identifying important immunological elements of subclinical collagen breakdown, which are not detectable in their early phase by X-ray or probing. The sensitivity of the new method is between 75 and 95 percent, up to three times more sensitive than BOP.

Nearly 50 percent of dental implants show signs of peri-implant inflammation. As a result, patients with implants have a 10-fold increased risk of periimplantitis and implant loss. For approximately 4 million affected implant patients in Germany, the sustainability of the replacement tooth supported by an implant can be improved through the use of the Dentognostics’ test used with QIAGEN’s reader which has been applied in various versions to a broad range of molecular and other point of need tests and of which thousands have been placed in the market.

The new technology also will be presented to international medical professionals (Hall 3, booth E84) at the MEDICA 2017 from 13 to 16 November in Düsseldorf.

Interested practices and press representatives can find additional information on this subject here or at: Dentognostics GmbH / IMOD GmbH Institute for Molecular Diagnostics Bonner Straße 84 – 42697 Solingen +49-(0)212-645 747 9-31.